Objectives: To investigate the relationship between chronic kidney disease and primary non-muscle-invasive bladder cancer. Methods: Disease outcomes were analyzed in 418 patients treated with transurethral resection for primary non-muscle-invasive bladder cancer, and were correlated to traditional risk factors as well as chronic kidney disease stage according to estimated glomerular filtration rate: ≥60 (G1-2), 45-59 (G3a) or <45 (G3b-5).
Introduction
Bladder cancer is one of the most common genitourinary malignancies, and approximately 70% of bladder cancers are NMIBC. 1 The incidence rates of bladder cancer have been rising in several countries. 2 The first-line treatment for NMIBC is transurethral bladder tumor resection, which in some cases is followed by a second TURBT and/or intravesical therapy. However, recurrence rates are 50-70%, and progression usually occurs in 5-20% of patients within 5 years. 3 The need for close surveillance and repeat treatment makes bladder cancer the most expensive malignancy to treat, and its management is a potential target for major healthcare savings. 4 In addition, once progression to muscle-invasive cancer occurs, 5-year survival is approximately just 50% after radical cystectomy. 5 Management in accordance with the risk of recurrence and progression is important to improve the outcomes, and also decrease the cost.
In current guidelines for NMIBC, the risk of recurrence and progression is classified on the basis of clinicopathological findings. 6, 7 Although these risk classifications do not include preoperative comorbidities or predisposing individual patient characteristics, several studies have reported that recurrence or progression in NMIBC increased for diabetics and smokers.
These factors are also closely related to CKD, which is defined as an abnormality of kidney structure or function. 10 Reduced renal function or CKD has been reported to be a risk factor for the clinical outcome of NMIBC, 11, 12 but it has not elucidated a relationship between CKD and EORTC risk tables, 13 which are widely-used conventional risk stratifications. The aim of the present study was to assess the detailed impact of CKD on recurrence and progression in NMIBC.
Methods

Patient population
The population in the present study consisted of 418 patients newly diagnosed with NMIBC who underwent TURBT between January 2006 and June 2013 at Hiroshima University Hospital or Hiroshima City Asa Hospital. Patients with previous or simultaneous upper tract urothelial carcinoma or pure CIS of the bladder, and those who had no follow-up visits after TURBT were excluded from this study. The present study retrospectively analyzed patient medical records. The pathological stage and grade for each patient was assigned in accordance with the Union for International Cancer Control TNM system (7th edition, 2009) 14 and the World Health Organization staging system (1973 version). 6 Follow up was carried out in accordance with an institutional protocol. The patients generally underwent cystoscopy every 3-4 months for 5 years and every 6 months thereafter.
Criteria for CKD of the Kidney Disease Improving Global Outcomes guidelines (2012 version) were defined as either of the following present for >3 months: markers of kidney damage (albuminuria, urine sediment abnormalities, electrolyte and other abnormalities due to tubular disorders, abnormalities detected by histology, structural abnormalities detected by imaging or history of kidney transplantation) or decreased GFR (<60 mL/min/1.73 m 2 ). 10 We used the latter criterion for the sake of clarity of the values. A revised equation from serum creatinine of the Japanese Society of Nephrology was used for calculating eGFR: eGFR = 194 9 Cr À1.094 9 age À0.297
(90.739 for female). 15 The patients who had normal eGFR (≥60) were described as G1-2 ("normal or high" to "mildly decreased") in accordance with the Kidney Disease Improving Global Outcomes guidelines. The patients with eGFR <60 were also classified into one of the following two stages of CKD on the basis of eGFR: G3a if eGFR = 45-59 ("mildly to moderately decreased") or G3b-5 if eGFR <45 ("moderately decreased" to "kidney failure").
Comorbidities were assessed retrospectively from the medical records and included: the CCI; 16 the presence of urinary abnormalities, such as hematuria, bacteriuria or proteinuria; history of smoking; hypertension; diabetes; and prior nephrectomy. Age-adjusted CCI values were calculated. 16 Hydronephrosis was assessed from reports of preoperative abdominal computed tomography by image-reading doctors in each institution, or from preoperative ultrasound if the statement was unclear.
Outcome definition
Recurrence-free survival was defined as the time from the first TURBT to the date of the first recurrence, and progression-free survival was defined as any upstaging to a T2 or higher disease. Patients who were still alive, and without recurrence and progression, were censored at the date of their last follow up.
T stage (Ta or T1), grade (1-3), tumor multiplicity (single or multiple), tumor size (<3 or ≥3 cm) and concurrent CIS were used to classify all patients into low-risk (Ta, grade 1, solitary, <3 cm and no CIS), intermediate-risk (all cases between low-and high-risk categories) and high-risk (T1, grade 3 or concurrent CIS) groups on the basis of the EAU guidelines updated in 2013, except for multifocal, >3 cm, recurrent Ta and grade 1-2 tumors as high-risk, because the present study was intended for primary tumors. 6, 13 
Statistical analysis
The characteristics of the patients in each of the CKD stages, and associations between the CKD stages and each of the risk groups were determined using v 2 -tests, Kruskal-Wallis tests, and one-way analysis of variance. Log-rank tests were used to compare the recurrence-or progression-free survivals of the patients in different CKD stages. Univariate and multivariate analyses using a Cox proportional hazards regression model were used to determine the adjusted HR, so that prognostic factors for each kind of survival could be identified. In all the analyses, a difference was considered significant when the P-value was <0.05.
Results
Patient characteristics
The study population consisted of 418 patients with newly diagnosed NMIBC. The median follow-up time was 40.0 months (range 1-104 months). During the observation period, death was observed in 33 patients (7.9%), but cancerspecific death was observed in just six patients (1.4%). Recurrence was observed in 237 patients (56.7%). Recurrence rates at 1, 2, and 5 years were 36.8%, 53.5% and 64.4%, respectively, and the median time to the first recurrence was 21.5 months. Progression was observed in 32 patients (7.7%). Patients were classified as G1-2, G3a, and G3b-5 CKD in 287 (68.7%), 98 (23.4%) and 33 (7.9%) cases, respectively. Among G3b-5 CKD, three patients were on dialysis. We examined whether other patient characteristics were compatible with CKD stage on the basis of generally accepted features of CKD. 10 As expected, the patients with G3b-5 CKD had the highest mean age, occurrence of proteinuria, hypertension and hydronephrosis, followed by G3a and G1-2 (Table 1) , whereas the rate of diabetes mellitus was not significantly different between the three CKD stages. Just two patients (0.5%) with G3a CKD had undergone prior nephrectomy.
Differences in the proportion of patients who received additional treatments, such as a second TURBT (G1-2, 5.9%; G3a, 10.2%; and G3b-5 CKD, 9.1%; P = 0.20) or intravesical bacillus Calmette-Gu erin therapy (G1-2, 16.7%; G3a, 18.4%; and G3b-5 CKD, 21.2%; P = 0.66), were not significant.
Higher CKD stage correlated with higher tumor stage and grade
We compared the established clinicopathological risk factors for recurrence and progression among the three CKD categories, and observed that the proportion of patients with T1 and with multiple tumors was significantly increased in the higher CKD stage ( Table 1 ). The proportion of histological grade 3 tumors was also higher in G3a and G3b-5 than in G1-2 CKD. However, the rate of concurrent CIS and tumor size was not different across the three categories. These results suggest that worse renal function is associated with a higher T stage and histological grade.
Predictors of recurrence and progression in accordance with CKD stage
We examined the clinical significance of CKD in recurrence-and progression-free survival. Patients with a higher CKD stage showed significantly shorter time to recurrence than those with a lower CKD stage (Fig. 1a) . Recurrence rates at 1 year and 5 years were 30.0% and 59.7% in G1-2, 49.2% and 74.8% in G3a, and 65.6% and 84.4% in G3b-5 CKD, respectively. In addition to G3b-5 CKD, the presence of hematuria, proteinuria, bacteriuria, T stage, histological grade, tumor size and tumor multiplicity were found to be significant factors for recurrence in the univariate analysis. In the multivariate analysis, G3b-5 CKD (P = 0.004; HR 1.87) and tumor size (P = 0.002; HR 1.53) were found to be independent predictors (Table 2) . Patients with G3b-5 CKD showed significantly shorter time to progression than those with <G3b (Fig. 1b) . Progression rates at 1 and 5 years were 2.5% and 9.5% in G1-2, 2.2% and 12.0% in G3a, and 9.7% and 22.6% in G3b-5, respectively. In addition to G3b-5, T stage, concurrent CIS, tumor grade and tumor multiplicity were also found to be significant predictive factors for progression in the univariate analyses. In the multivariate analysis, G3b-5 (P = 0.019; HR 2.96), tumor grade (P = 0.017; HR 2.42) and tumor multiplicity (P = 0.028; HR 2.65) were found to be independent predictors (Table 2) . Hypertension, the most important risk factor of CKD, did not remain as a significant predictor for both recurrence and progression (Table 2) . 10 Cancer-specific and non-cancer-related survival according to CKD stage
Patients with G3b-5 CKD had the shortest non-cancer-related survival, followed by G3a and G1-2 ( Fig. 2a ; P = 0.005), consistent with the age-adjusted CCI score as shown in Table 1 . However, cancer-related survival did not differ significantly among the CKD stages ( Fig. 2b ; P = 0.79).
Association of CKD stage with EAU risk group stratification
We classified all patients into low-(n = 42), intermediate-(n = 180) and high-risk (n = 196) groups in accordance with the EAU stratification, and compared the percentage of each CKD stage within the three risk groups (Table 3 ). The patients with G1-2 CKD accounted for 88% of the low-risk group, but the proportion was decreased in the intermediateand high-risk groups. However, the proportion of patients with G3a and with G3b-5 increased from low-to intermediate-, to high-risk (P < 0.001). Figure 3 shows the survival rates of different CKD stages for the low-, intermediate-and high-risk groups. Higher CKD stages significantly correlated with worse recurrence-free survival for the intermediate-(P = 0.006; Fig. 3b ) and high-risk (P = 0.019; Fig. 3c) 
Discussion
Predicting recurrence and progression of NMIBC is critical for deciding on optimal treatment delivery and for determining surveillance schedules. Many factors have been reported for risk stratification, including the multiple clinicopathological variables of the EORTC risk tables. However, each risk stratification model has its limitations, and there is a need for more accurate prediction. 17, 18 Xylinas et al., for example, reported that the EORTC risk tables and the Spanish Urological Club for Oncological Treatment scoring models show poor discrimination for both recurrence and progression in NMIBC patients. 18 Previously, CKD, especially at stages higher than G3b (eGFR <45), has been shown in a retrospective cohort study of 1 190 538 adults to have a higher risk for urothelial carcinoma incidence. The HRs were, respectively, 1.12 (95% CI 0.99-1.27), 1.42 (95% CI 1.21-1.67), and 1.48 (95% CI 1.19-1.85) in patients with eGFR 45-59, 30-44 and <30 compared with normal eGFR. 19 We found CKD G3b-5 (eGFR <45), while eGFR <60 in the previous reports, 11, 12 to be an independent predictor for both recurrence and progression of NMIBC in the present study. The EORTC risk tables define tumor size, multiplicity, and the prior recurrence rate as the most important prognostic factors for recurrence, and T stage, tumor grade and the presence of CIS as most important for predicting progression. 13 We found similar risk factors to be important in the univariate analysis (Table 2) , with the exception of prior recurrence rate.
However, we also found that CKD stage was strongly associated with the conventional risk groups, and the conventional risk factors were no longer independent predictors in our multivariate models when CKD stage was included. The present results suggest that adding CKD stage to the conventional risk factors might improve the accuracy of risk stratification, or could even replace some of the conventional risk factors.
Although the mechanism by which CKD contributes to the recurrence and progression of NMIBC is unknown, cytokeratin 18 might play a role in the worse outcome of bladder cancer in patients with CKD. Urinary cytokeratin 18 concentration, one of the urine tumor markers, 20 is also increased in patients with CKD as a surrogate for increased inflammation. 21 Inflammatory proteins in patients with CKD might increase oncogenic activity, resulting in an earlier recurrence and more aggressive tumor behavior. 11 The rate of death from NMIBC was low in the present study and overall in the general population. 6 It is therefore not surprising that we found no association between CKD and cancer-specific survival. However, we have a possible hypothesis that more patients with G3b-5 than with the others might ultimately die for other reasons despite the progression of bladder cancer because of their comorbidities, resulting in the elimination of the difference of their cancerspecific survivals. It would be important to further study the effect of medical comorbidities on mortality in patients with NMIBC.
CKD can reflect a summation of other parameters, such as age, prior smoking history and other medical conditions, such as diabetes, hypertension and cardiovascular disease. 10 Hydronephrosis is another factor that contributes to renal dysfunction. It is known to be associated with advanced stage bladder cancer and upper tract urothelial cancer. 22, 23 Although hydronephrosis was significantly associated with CKD (Table 1) , it was not found to be an independent predictor of the clinical outcome of NMIBC (Table 2 ). There was a possibility that insufficiency of the cases with hydronephrosis or their comorbidity in our database masked accurate influence. Two of the six cases with hydronephrosis died of other causes without progression, whereas only one with G3b-5 had experienced progression. Cancer-specific survival. Cancer-specific survival did not differ significantly among the CKD stages. G1-2: eGFR ≥60; G3a: eGFR 45-59; G3b-5: eGFR <45. Proteinuria is a parameter used to classify the severity of CKD. Although a high urine albumin-to-creatinine ratio was shown to be a risk factor for bladder cancer incidence in a prior study, we found no impact of proteinuria as an independent predictor for recurrence or progression. 24 As urine quantitative exams were not carried out in the present study, the presence of proteinuria was investigated qualitatively using a dipstick test. Further study is required to confirm the impact of proteinuria.
The current results raise the question of whether treatment of CKD could improve the clinical outcome of NMIBC. Although we did not include medication history in the present study, such as antihypertensive agents, several reports have suggested that antihypertensive therapy inhibits CKD progression and the risk of cardiovascular disease. 10 The first-line of treatment recommended in the Kidney Disease Improving Global Outcomes guidelines is renin-angiotensin system blockade, which can be achieved with angiotensinconverting enzyme blockers or angiotensin II receptor blockers. 10 Angiotensin II is a key biological peptide in the reninangiotensin system, but might also be involved in carcinogenesis. The angiotensin type I receptor is expressed in various malignancies, and has been reported to enhance tumor growth, metastasis and angiogenesis. 25 Yuge et al. reported that angiotensin-converting enzyme blockers or angiotensin II receptor blockers significantly reduced the rate of recurrence in patients with NMIBC. 26 Treatment of CKD with renin-angiotensin system inhibitors might therefore improve the clinical outcome of NMIBC.
The present study had several important limitations. First, our results are based on a retrospective study with a fairly limited number of patients. As for G4-5 CKD, there were just nine cases. Thus, until future prospective studies certify the relationship between CKD and NMIBC, CKD might not yet be considered an authentic risk factor with only the present results. Second, the study did not include recurrent tumors, and we did not consider the rate of repeat TURBT or intravesical therapy, although there were no statistically significant differences between the CKD stages. Third, the present data did not include a number of disease states related to bladder cancer. For example, chronic urinary retention, which can cause chronic inflammation associated with bladder cancer, and hydronephrosis, which reduces renal function. 27 Finally, we used the equation of the Japanese Society of Nephrology to estimate GFR, as it has been found most suitable for Japanese patients, 15 whereas the CKD-epidemiology collaboration formula was used in the Kidney Disease Improving Global Outcomes guidelines. 10 In conclusion, CKD is an independent predictor of recurrence and progression in primary NMIBC. In addition, it is associated with worse non-cancer-related mortality. CKD stage is strongly associated with the NMIBC risk groups as defined by the EAU guidelines. The present results suggest that adding CKD stage to the conventional risk factors could improve the accuracy of risk stratification. Confirmation of the present results by a prospective study is desired.
Editorial Comment
Editorial Comment to Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer Bladder cancer (BC) has a complex biology. We know a great deal about the role of smoking exposure or workplace chemicals, such as aromatic amine, their pathogenetic role and prognostic meaning. Indeed, the link between chronic kidney disease (CKD) and BC occurrence has only been suggested, and definitely deserves attention. As a matter of fact, CKD affects 5-10% of the population, and could therefore be a relevant cause of BC.
1, 2 We also know that BC is to some extent merely the name for many diseases with different biological and clinical behaviors. Therefore, risk stratification is certainly of utmost importance for a tumor that has significant prevalence and that has expensive management. Classic risk factors of non-muscle-invasive bladder cancer, such as stage, grade, 3-month recurrence, recurrence rate, multiplicity and volume, are well established and summarized in wellknown recurrence and risk stratification calculators. Beyond them, the complex biology of the tumor might harbor unknown and unexpected factors. Kobatake et al. therefore
